Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Research by Oxford University academics has found little evidence of a relationship between screen time and wellbeing in adolescents. Based on data from more than 17,000 teenagers, the study casts doubt on the widely accepted notion that spending time online, gaming or watching TV, especially before bedtime, can damage young people’s mental health.

© Shutterstock

“Implementing best practice statistical and methodological techniques we found little evidence for substantial negative associations between digital-screen engagement and adolescent wellbeing,” said Amy Orben, a researcher at the Oxford Internet Institute (OII) and College Lecturer at the Queen’s College, University of Oxford.

“While psychological science can be a powerful tool for understanding the link between screen use and adolescent wellbeing, it still routinely fails to supply stakeholders and the public with high-quality, transparent and objective investigations into growing concerns about digital technologies. Analysing three different datasets, which include improved measurements of screen time, we found little clear-cut evidence that screen time decreases adolescent wellbeing, even if the use of digital technology occurs directly before bedtime,” said Professor Andrew Przybylski, Director of Research at the OII and co-author on the study.

The research found that adolescents’ total screen time per day had little impact on their mental health, both on weekends and weekdays. It also found that the use of digital screens two hours, one hour or 30 minutes before bedtime didn’t have clear associations with decreases in adolescent wellbeing, even though this is often taken as a fact by media reports and public debates.

Read more (University of Oxford website)

Similar stories

New form of gift wrap drives male reproductive success

General Research

A study from the Department of Physiology, Anatomy and Genetics (DPAG) has identified a new communication mechanism that ensures the transfer of a complex mix of signals and nutrients required for successful reproduction between males and females.

PRINCIPLE trial finds antibiotics azithromycin and doxycycline not generally effective treatments for COVID-19

Coronavirus COVID-19 General Research

In March 2020, the UK-wide Platform Randomised trial of INterventions against COVID-19 In older people (PRINCIPLE) trial was established as a flexible, platform randomised clinical trial to test a range of potential treatments for COVID-19 that might be suitable for use in the community to help people recover more quickly and prevent the need for hospital admission. The trial is one of three national platform trials for COVID-19 treatments, and complements the RECOVERY and REMAP-CAP trials that focus on hospitalised patients.

Early animal studies yield promising results for new potential COVID-19 vaccine

Coronavirus COVID-19 General Research

Studies carried out in the MRC Human Immunology Unit (MRC HIU) in collaboration with the Pirbright Institute have shown that a new potential vaccine against COVID-19, named RBD-SpyVLP, produces a strong antibody response in mice and pigs, providing vital information for the further development of the vaccine. Although this type of vaccine is not a competitor for the first wave of vaccines, it is hoped that it will be useful as a standalone vaccine or as a booster for individuals primed with a different COVID-19 vaccine.

Just over half of British Indians would take COVID vaccine

Coronavirus COVID-19 General Research

University of Oxford researchers from the Department of Physiology, Anatomy and Genetics (DPAG) and the Department of Psychiatry, in collaboration with The 1928 Institute, have published a major new study on the impact of COVID-19 on the UK’s largest BME population.

Investigating New Treatment for Schizophrenia

General Innovation Research

A partnership between University of Oxford, the Earlham Institute, and the global pharmaceutical companies Biogen Inc and Boehringer Ingelheim is announced today to investigate a new drug target for the treatment of schizophrenia.